ENANTA PHARMACEUTICALS reports 2018 executive compensation

CEO Jay R. Luly receives $4.5M

ENANTA PHARMACEUTICALS reported fiscal year 2018 executive compensation information on January 18, 2019.

In 2018, five executives at ENANTA PHARMACEUTICALS received on average a compensation package of $2,068,841, a 5% decrease compared to previous year.

Average pay of disclosed executives at ENANTA PHARMACEUTICALS

Jay R. Luly, Chief Executive Officer, received $4,508,737 in total, which increased by 5% compared to 2017. 59.54% of Luly's compensation, or $2,684,490, was in option awards. Luly also received $355,688 in non-equity incentive plan, $611,178 in salary, $838,530 in stock awards, as well as $18,851 in other compensation.

Yat Sun Or, Chief Scientific Officer, received a compensation package of $1,524,003, which decreased by 14% compared to previous year. 41.39% of the compensation package, or $630,855, was in option awards.

Nathalie Adda, Chief Medical Officer, earned $1,514,076 in 2018, a 14% decrease compared to previous year.

Paul J. Mellett, Chief Financial Officer, received $1,421,277 in 2018, which decreases by 11% compared to 2017.

Nathaniel S. Gardiner, General Counsel, earned $1,376,111 in 2018, a 9% decrease compared to previous year.

ENANTA PHARMACEUTICALS' fiscal year ends on September 30.